Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis

Brionna N. Hudson, Hollyann R. Jacobs, Alexander Philbrick, Xiaolong A. Zhou, Michelle M. Simonsen, Julie A. Safirstein, Shannon M. Rotolo*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Elexacaftor/tezacaftor/ivacaftor (ELX-TEZ-IVA) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator shown to improve lung function and reduce sweat chloride in people with Cystic Fibrosis (CF). The only commonly reported dermatologic adverse effect with CFTR modulators including ELX-TEZ-IVA is rash. In this case series, we describe 19 patients who reported new onset or worsening of acne after initiation of this drug to their CF pharmacist or another member of their CF care team. The mechanism and frequency of this adverse effect is unknown.

Original languageEnglish (US)
Pages (from-to)1066-1069
Number of pages4
JournalJournal of Cystic Fibrosis
Issue number6
StatePublished - Nov 2022


  • “Acne vulgaris”
  • “Cystic fibrosis”
  • “Drug-Related side effects and adverse reactions”
  • “Elexacaftor”

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis'. Together they form a unique fingerprint.

Cite this